Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ezetimibe.

Harold Bays1

  • 1Louisville Metabolic and Atherosclerosis Research Center, 3288 Illinois Ave, Louisville, KY 40213, USA.

Expert Opinion on Investigational Drugs
|November 20, 2002
PubMed
Summary
This summary is machine-generated.

Ezetimibe, a cholesterol absorption inhibitor, effectively lowers LDL-C. It highlights intestinal cholesterol absorption as a key source, advancing understanding of lipid metabolism and treatment for dyslipidemia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.

Journal of medical economics·2026
Same author

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.

Lancet (London, England)·2025
Same author

Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: <i>post-hoc</i> analysis of the SURMOUNT-5 trial.

European heart journal open·2025
Same author

Editorial: Exploring the nuances of obesity in Asian populations.

Obesity pillars·2025
Same author

Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.

The New England journal of medicine·2024
Same author

Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.

Diabetes, obesity & metabolism·2024
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Area of Science:

  • Biochemistry
  • Pharmacology
  • Metabolic Research

Background:

  • Low-density lipoprotein cholesterol (LDL-C) is influenced by hepatic and peripheral synthesis.
  • Intestinal cholesterol absorption is a significant, often underestimated, contributor to LDL-C levels.

Purpose of the Study:

  • To elucidate the role of intestinal cholesterol absorption in LDL-C regulation.
  • To explore how ezetimibe influences cholesterol metabolism and impacts lipid profiles.
  • To re-evaluate existing paradigms in cholesterol metabolism research.

Main Methods:

  • Investigated the mechanism of action of ezetimibe as a cholesterol absorption inhibitor.
  • Analyzed the impact of ezetimibe on lipid parameters (LDL-C, triglycerides, HDL-C) in monotherapy and combination with statins.

Related Experiment Videos

  • Examined factors influencing cholesterol absorption, including genetics, diet, and nuclear receptors.

    • Main Results:

    • Ezetimibe significantly reduces LDL-C levels.
    • Ezetimibe demonstrates favorable effects on triglyceride and high-density lipoprotein cholesterol.
    • The drug's action underscores the importance of intestinal cholesterol absorption, challenging previous assumptions.

    Conclusions:

    • Ezetimibe provides an effective treatment option for dyslipidemia.
    • The study of ezetimibe has reshaped understanding of cholesterol metabolism pathways.
    • Ezetimibe promotes further research into lipid metabolism and therapeutic strategies.